79 related articles for article (PubMed ID: 2464198)
1. Defective fibrinolytic response in atherosclerotic patients--effect of iloprost and its possible mechanism of action.
Bertelé V; Mussoni L; del Rosso G; Pintucci G; Carriero MR; Merati MG; Libretti A; de Gaetano G
Thromb Haemost; 1988 Oct; 60(2):141-4. PubMed ID: 2464198
[TBL] [Abstract][Full Text] [Related]
2. The inhibitory effect of aspirin on fibrinolysis is reversed by iloprost, a prostacyclin analogue.
Bertelé V; Mussoni L; Pintucci G; del Rosso G; Romano G; de Gaetano G; Libretti A
Thromb Haemost; 1989 Apr; 61(2):286-8. PubMed ID: 2473539
[TBL] [Abstract][Full Text] [Related]
3. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease.
Musiał J; Wilczyńska M; Sładek K; Cierniewski CS; Nizankowski R; Szczeklik A
Prostaglandins; 1986 Jan; 31(1):61-70. PubMed ID: 2419945
[TBL] [Abstract][Full Text] [Related]
5. [t-PA and PAI in patients with Raynaud's syndrome in treatment with a stable prostacyclin analog].
Pola P; de Martini D; Gerardino L
Angiologia; 1992; 44(2):62-6. PubMed ID: 1378247
[TBL] [Abstract][Full Text] [Related]
6. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE
Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolytic response to venous occlusion compared to physical stress test in young patients with coronary artery disease.
Nikfardjam M; Graf S; Beckmann R; Hornykewycz S; Koller-Strametz J; Binder BR; Huber K
Thromb Haemost; 1999 Sep; 82 Suppl 1():80-4. PubMed ID: 10695493
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
11. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo.
Lang NN; Gudmundsdóttir IJ; Boon NA; Ludlam CA; Fox KA; Newby DE
J Am Coll Cardiol; 2008 Jul; 52(1):33-9. PubMed ID: 18582632
[TBL] [Abstract][Full Text] [Related]
12. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion.
Speidl WS; Zeiner A; Nikfardjam M; Geppert A; Jordanova N; Niessner A; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
J Am Coll Cardiol; 2005 Jan; 45(1):30-4. PubMed ID: 15629369
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
14. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tissue plasminogen activator inhibitor by defibrotide in atherosclerotic patients.
Violi F; Ferro D; Alessandri C; Quintarelli C; Saliola M; Balsano F
Semin Thromb Hemost; 1989 Apr; 15(2):226-9. PubMed ID: 2501872
[TBL] [Abstract][Full Text] [Related]
16. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolytic activity during hemodialysis: a biocompatibility-related phenomenon.
Martin-Malo A; Velasco F; Rojas R; Castillo D; Rodriguez M; Torres A; Aljama P
Kidney Int Suppl; 1993 Jun; 41():S213-6. PubMed ID: 8320924
[TBL] [Abstract][Full Text] [Related]
18. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.
Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N
Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090
[TBL] [Abstract][Full Text] [Related]
19. [Fibrinolytic activity and tissue plasminogen activator level in healthy individuals prior to and after a ten-minute venous stasis].
Kubicka A; Libura M; Sacha T; Swadźba J; Undas A; Wandzilak M
Pol Tyg Lek; 1993 Feb 1-8; 48(5-6):116-9. PubMed ID: 8361905
[TBL] [Abstract][Full Text] [Related]
20. Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunosuppression therapy.
Sartori MT; Rigotti P; Marchini F; Spiezia L; Baldan N; Furian L; Varvarikis C; Girolami A
Transplantation; 2003 Apr; 75(7):994-8. PubMed ID: 12698086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
